Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05061017
Title Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Diwakar Davar

lung non-small cell carcinoma

skin melanoma

colorectal cancer


Cyclophosphamide + Nivolumab + PG545

Nivolumab + PG545

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.